{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:31:00Z","timestamp":1761514260065,"version":"3.37.3"},"reference-count":23,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare, in real\u2010life settings, the retention rates of initial anti\u2010tumor\u2010necrosis factor (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>) treatments (etanercept [<jats:styled-content style=\"fixed-case\">ETN<\/jats:styled-content>], adalimumab [<jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content>] and infliximab [<jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content>]) used as first\u2010line biotherapy for axial spondyloarthritis (axSpA), and evaluate treatment switches to another anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> inhibitor in the event of treatment failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed the medical records of all SpA patients (Assessment in Ankylosing Spondylitis International Working Group axial criteria) treated with <jats:styled-content style=\"fixed-case\">ETN<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> IFX<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content> between 2001 and February 2015. Drug retention rates were calculated using the Kaplan\u2010Meier method and compared by means of the Cox extended model. Sub\u2010analyses were performed according to discontinuation reasons.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 249 SpA patients analyzed (135 radiographic cases, 114 non\u2010radiographic), 102 received <jats:styled-content style=\"fixed-case\">ETN<\/jats:styled-content>, 62 <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content>, and 85 <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content>. In total, 103 discontinued treatment. The retention rates of <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> ADA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">ETN<\/jats:styled-content> were 67%, 59% and 56% after 3\u00a0years; 62%, 42% and 47% after 5\u00a0years; 55%, 42% and 24% after 8\u00a0years; 53%, 42% and 12% after 10\u00a0years, respectively. In multivariate analyses, the predictive factors for retention were: low <jats:styled-content style=\"fixed-case\">BASDAI<\/jats:styled-content> score (hazard ratio [<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>]: 1.02 [1.01\u20101.04]), high C\u2010reactive protein levels (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>: 0.98 [0.97\u20100.99]), concomitant disease\u2010modifying therapy (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>: 0.4 [0.21\u20100.75]), and radiographic SpA (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>: 1.5 [1.0\u20102.52]). In total, 61 patients switched to another anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> therapy. No difference was observed among the three anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> therapies regarding median retention duration, although the retention rate proved higher for treatment switches from one monoclonal antibody to another.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The retention rate in SpA patients proved high, with retention for <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content> superior to that of <jats:styled-content style=\"fixed-case\">ETN<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13375","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T03:28:56Z","timestamp":1535686136000},"page":"1986-1992","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Retention rates of adalimumab, etanercept, and infliximab as first\u2010 or second\u2010line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France)"],"prefix":"10.1111","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-0720","authenticated-orcid":false,"given":"Martin","family":"Soubrier","sequence":"first","affiliation":[{"name":"Rhumatologie Clermont\u2010Ferrand University Hospital H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[{"name":"DRCI Clermont\u2010Ferrand University Hospital H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelique","family":"Fan","sequence":"additional","affiliation":[{"name":"Rhumatologie Clermont\u2010Ferrand University Hospital H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Frayssac","sequence":"additional","affiliation":[{"name":"Rhumatologie Clermont\u2010Ferrand University Hospital H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Couderc","sequence":"additional","affiliation":[{"name":"Rhumatologie Clermont\u2010Ferrand University Hospital H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Malochet\u2010Guinamand","sequence":"additional","affiliation":[{"name":"Rhumatologie Clermont\u2010Ferrand University Hospital H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Rhumatologie Clermont\u2010Ferrand University Hospital H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Tatar","sequence":"additional","affiliation":[{"name":"Rhumatologie Clermont\u2010Ferrand University Hospital H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Tournadre","sequence":"additional","affiliation":[{"name":"Rhumatologie Clermont\u2010Ferrand University Hospital H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Jacques","family":"Dubost","sequence":"additional","affiliation":[{"name":"Rhumatologie Clermont\u2010Ferrand University Hospital H\u00f4pital Gabriel Montpied Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-013-2772-6"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205322"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1941"},{"issue":"6","key":"e_1_2_7_5_1","first-page":"958","article-title":"Anti\u2010TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA","volume":"27","author":"Pavelka K","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124446"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq008"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker281"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.131797"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201933"},{"issue":"6","key":"e_1_2_7_11_1","first-page":"857","article-title":"Drug survival of the first course of anti\u2010TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database","volume":"31","author":"Scir\u00e8 CA","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket249"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2014.918173"},{"issue":"3","key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1756-185X.12264","article-title":"Factors associated with withdrawal of the anti\u2010TNF\u03b1 biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry","volume":"17","author":"Mok CC","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20258"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2929-7"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206616"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev001"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150372"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev392"},{"issue":"3","key":"e_1_2_7_21_1","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta\u2010analysis of drug registries and health care databases","volume":"55","author":"Souto A","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep422"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38140"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13375","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13375","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.13375","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T02:40:21Z","timestamp":1694313621000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,30]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/1756-185X.13375"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13375","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"type":"print","value":"1756-1841"},{"type":"electronic","value":"1756-185X"}],"subject":[],"published":{"date-parts":[[2018,8,30]]},"assertion":[{"value":"2017-10-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}